New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Subscribe To Our Newsletter & Stay Updated
